EDIT - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Editas Corp

Editas Medicine, Inc. (EDIT) attracts leading geneticists through generous stock options and R&D. The year-over-year sales growth rate for the TTM reflects the dynamics of this strategy, with the figure fixed at 7.50. However, the global technological divide complicates license exports, and the operating model relies on external CROs, whose work is strictly monitored by management to minimize risks.
Editas Corp (EDIT) - פילוחי מדדים ודוחות פיננסיים

This indicator reflects the dynamics of total revenue changes over a rolling year, allowing for an assessment of business scaling rates relative to the previous period. An analysis of the YoY revenue growth for Editas Medicine, Inc. (EDIT) over a rolling 12-month period confirms a pre-commercial development stage, as the absence of sales coupled with high CRISPR research costs renders this metric a tool for recording the lack of operating income.